After years of treatment intensification, a new focus in metastatic hormone-sensitive prostate cancer is de-escalation. Trials like ADREAM are evaluating planned treatment interruptions for patients with excellent responses, aiming to provide 'treatment-free intervals' that improve quality of life without sacrificing efficacy.

To avoid committing young patients to lifelong daily medication, oncologists treating desmoid tumors with oral agents will consider "treatment holidays." After achieving maximum response, they may pause therapy and restart only upon symptomatic progression, balancing efficacy with quality of life.

For non-advanced systemic mastocytosis, new drugs are differentiated by their side effect profiles, not just efficacy. Avapritinib can cause cognitive effects as it crosses the blood-brain barrier, while bezuclastinib may cause transient liver enzyme elevation. This allows for personalized treatment choices based on patient tolerability and lifestyle.

Recent drug approvals for non-advanced systemic mastocytosis were based on patient-reported outcomes (PROs) measuring symptom improvement. While biomarkers like serum tryptase often correlate, the primary measure of success is the patient's subjective experience. This presents a challenge for monitoring effectiveness in routine clinical practice outside of formal trials.

Beyond rigid trial protocols, a flexible approach to first-line T-DXd is practical and patient-centered. This includes discussing treatment breaks for holidays or switching to a less burdensome maintenance regimen (like subcutaneous HP) if a patient is tired of frequent clinic visits, prioritizing their quality of life.

Avapritinib is dosed at 200mg for advanced systemic mastocytosis (SM) but only 25mg for indolent SM. This tenfold difference is not based on tolerance but on the goal of therapy: extending survival in advanced SM versus improving quality of life without significant toxicity in indolent SM, where survival is near-normal.

While continuous therapy remains the official standard of care for mHSPC, there's a growing consensus for individualized de-intensification. For patients with a sustained, undetectable PSA (e.g., for two years), clinicians are increasingly comfortable discussing stopping all treatments to improve quality of life and reduce toxicity.

For older CLL patients, stopping acalabrutinib after 18 months results in relapse within a year for half of them. However, their overall survival remains identical to those who continue treatment, suggesting a "drug holiday" is a safe option for managing side effects or patient preference without long-term detriment.

The doublet's unique dosing schedule (twice-weekly pills for three weeks, then one week off) is crucial for its long-term success. This "recovery week" per cycle is thought to reduce cumulative toxicity, allowing patients to stay on this highly effective therapy for extended periods.